Firefly Neuroscience terminated Paul Krzywicki as Chief Financial Officer effective September 24, 2026, citing no disagreements regarding operations or policies. The company appointed Jessica Paz as Chief Accounting Officer effective September 8, 2026. Ms. Paz receives an annual base salary of $215,000 and a stock option to purchase 50,000 shares vesting over four years. She brings prior accounting leadership experience from Genvid Holdings and VITECH Systems Group. Firefly Neuroscience operates in the biotechnology sector, developing treatments for neurological disorders.

On June 25, 2026, Firefly Neuroscience, Inc. and an accredited investor mutually agreed to terminate a securities purchase agreement dated May 6, 2026. The agreement would have seen the company issue up to 666,667 units at $1.50 per unit for aggregate gross proceeds of up to $1,000,000. The company operates in the healthcare technology industry, developing neuroscience-based diagnostic and therapeutic solutions.

On June 18, 2026, Gil Issachar transitioned from Chief Technology Officer to Head of AI and Neuroscience under a new employment agreement with Deel Innovation Ltd. Consequently, the board of directors determined that Issachar is no longer classified as a Section 16 or executive officer of the company. Firefly Neuroscience operates in the healthcare technology industry, providing AI-driven neuroscience solutions.